SEC Form 10-Q Summary
Filing identity: The provided filing is for Aerpio Pharmaceuticals, Inc., not Whitehawk Therapeutics, Inc. It covers the quarter and six months ended June 30, 2021, and was filed August 11, 2021. Aerpio operated as a clinical-stage biopharmaceutical company developing Tie2/VE-PTP-targeting therapies, principally razuprotafib and related programs.
Business Context and Reporting Period
- Aerpio’s lead glaucoma/ocular-hypertension Phase 2 trial of razuprotafib met its primary endpoint at twice-daily dosing, but the reduction in intraocular pressure was not considered sufficient to advance to Phase 3.
- The company was pursuing strategic alternatives for its clinical assets and cash resources and entered into a merger agreement with Aadi Bioscience on May 16, 2021. The merger was expected to close in the second half of 2021, subject to shareholder approval and other conditions.
- Aerpio had five full-time employees as of June 30, 2021, following a January 2021 workforce reduction of seven employees, or approximately 58% of its workforce.
- The financial statements are unaudited condensed consolidated statements prepared under U.S. GAAP.
Financial Results and Key Metrics
| Metric | Three months ended June 30, 2021 | Three months ended June 30, 2020 | Six months ended June 30, 2021 | Six months ended June 30, 2020 |
|---|---|---|---|---|
| License revenue | $0 | $15.0 million | $0 | $15.0 million |
| Research and development expense | $0.7 million | $3.5 million | $2.9 million | $5.4 million |
| General and administrative expense | $4.1 million | $2.2 million | $6.2 million | $4.5 million |
| Restructuring expense | $0 | $0 | $1.2 million | $0 |
| Total operating expenses | $4.8 million | $5.7 million | $10.4 million | $9.9 million |
| Net income (loss) | $(4.4) million | $9.3 million | $(8.8) million | $5.4 million |
| Basic and diluted EPS | $(0.09) | $0.23 | $(0.19) | $0.13 |
- June 30, 2021 cash and cash equivalents were $36.8 million, down from $42.6 million at December 31, 2020.
- Total assets were $37.4 million and total liabilities were $2.2 million at June 30, 2021. Stockholders’ equity was $35.2 million.
- Accumulated deficit increased to $155.4 million from $146.6 million at December 31, 2020.
- Net cash used in operating activities was $5.9 million for the first six months of 2021, compared with $6.4 million of operating cash provided in the prior-year period, which benefited from the $15.0 million Gossamer license payment.
- Net cash provided by financing activities was $0.1 million, primarily from stock-option and warrant exercises. There was no investing activity during the first six months of 2021.
- The filing reports no debt outstanding and no material off-balance-sheet arrangements.
- Stock-based compensation expense was $0.9 million in the first six months of 2021.
Material Changes Versus the Prior Comparable Period
- Revenue and profitability declined sharply because the prior-year period included a one-time $15.0 million payment under the amended Gossamer license agreement. No comparable license payment or milestone was recognized in 2021.
- Research and development expense decreased 80% in the second quarter and 45% for the six-month period, primarily because of reduced clinical-trial activity and the wind-down of COVID-19-related work.
- General and administrative expense increased 85% in the second quarter and 38% for the six-month period, primarily due to merger-related transaction costs and expenses.
- The January 2021 restructuring generated approximately $1.2 million of severance expense. Approximately $0.7 million remained accrued at June 30, 2021 and was expected to be substantially paid by December 31, 2021.
- The company disposed of all furniture and equipment and recorded a $93,285 loss on disposal.
- Cash declined by $5.8 million during the first six months of 2021, compared with a $6.3 million increase in the prior-year period.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management stated that existing cash and cash equivalents were expected to fund the current operating plan through at least the fourth quarter of 2022, absent future financings or strategic partnerships. Management also cautioned that additional capital may be required sooner if operating plans change.
- The proposed Aadi merger included a contingent $155.0 million PIPE financing. The financing was contingent on the merger closing. Current Aerpio shareholders were expected to own approximately 14.7% of the combined company on a fully diluted basis after the PIPE, versus approximately 29.6% for former Aadi shareholders and 55.7% for PIPE investors.
- Merger conditions included shareholder approvals, completion of the PIPE financing, and Aerpio maintaining at least $10.0 million of cash and cash equivalents. Certain termination circumstances could require Aerpio to pay Aadi a $2.0 million termination fee and up to $750,000 of expenses.
- Six purported shareholder lawsuits had been filed in connection with the merger, alleging inadequate consideration and omissions or misstatements in the proxy materials. The company considered the claims without merit but could not predict the outcome or related costs. A separate books-and-records demand had also been received.
- COVID-19 affected clinical-trial recruitment, monitoring, and operations. The I-SPY trial discontinued razuprotafib after 21 patients, and recruitment in the RESCUE trial stopped after 31 patients. RESCUE data were limited, with one death in each treatment group and a dose-dependent reduction in blood pressure.
- Clinical work for RESCUE was substantially complete as of June 30, 2021. Razuprotafib, ARP-1536, and the bispecific antibody remained subject to significant clinical, regulatory, financing, intellectual-property, and commercialization risks.
- Future Gossamer milestones and royalties were fully constrained for accounting purposes at June 30, 2021; no clear value was recognized for those potential payments.
- Management concluded that disclosure controls and procedures and internal control over financial reporting were effective as of June 30, 2021, with no material changes during the quarter.
Most Important Facts for Investors to Verify
- Confirm the issuer: the supplied filing is Aerpio Pharmaceuticals, Inc., despite the request metadata identifying Whitehawk Therapeutics, Inc.
- Verify whether the Aadi merger and related $155.0 million PIPE financing closed, and review the final ownership percentages and consideration.
- Review the final status and potential financial exposure of the merger-related shareholder litigation and books-and-records demand.
- Assess cash burn, the stated fourth-quarter-2022 liquidity horizon, and whether additional financing was obtained or became necessary.
- Determine whether Gossamer’s GB004 program generated subsequent milestones, royalties, or other payments, noting that none were recognized in the reported period.
- Evaluate the remaining clinical and regulatory prospects for razuprotafib and other legacy assets, particularly after the limited COVID-19 trial data and the decision not to advance the glaucoma program to Phase 3.